We are live on ! Find out more
RGNX icon

Regenxbio

166 hedge funds and large institutions have $785M invested in Regenxbio in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 65 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $3.64M | Put options by funds: $2.54M

2.6% less ownership

Funds ownership: 78.89%76.29% (-2.6%)

7% less funds holding

Funds holding: 179166 (-13)

23% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 65

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

28% less capital invested

Capital invested by funds: $1.08B → $785M (-$298M)

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Holders
166
Holders Change
-13
Holders Change %
-7.26%
% of All Funds
3.34%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
19
Increased
50
Reduced
65
Closed
31
Calls
$3.64M
Puts
$2.54M
Net Calls
+$1.1M
Net Calls Change
+$410K

RGNX Hedge Fund Activity: Q3 2020 in Review

166 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2020, worth a combined $785M — down 28% from $1.08B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of RGNX and 19 opened new positions — a net loss of 12 holders — while 65 trimmed existing stakes and 50 added.

The largest buyer was UBS Group, adding an estimated $11.8M. The largest seller was Wellington Management Group, cutting an estimated $9.86M.

  • 166 institutional investors held Regenxbio (RGNX) as of Q3 2020, down from 179 in Q2 2020.
  • Funds reported $785M of Regenxbio stock for Q3 2020, down 28% quarter-over-quarter.
  • 19 funds opened new Regenxbio positions in Q3 2020 and 31 closed out, a net change of -12 holders.
  • The largest Regenxbio buyer in Q3 2020 was UBS Group, an estimated $11.8M added.
  • The largest Regenxbio seller in Q3 2020 was Wellington Management Group, an estimated $9.86M sold.

Based on aggregated 13F filings for Q3 2020.